开年高管密集变动,医药行业人事“地震”

中国药店
Feb 05

2026年伊始,全球及中国医药行业迎来了一波高管人事变动潮。从跨国巨头中国区的“老将回归”与“内部提拔”,到本土药企为创新、国际化与内部重构而进行的人才布局,一系列调整清晰勾勒出行业应对市场变化、进行战略校准的动态。跨国药企中国区变动1. 默克中国自2026年2月1日起,罗杰仁 (Rogier Janssens)正式担任默克中国总裁,同时他已于1月1日起兼任默克生命科学中国负责人。此次任命属于“...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10